Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.52 |
| ▸ | RAC1 | P63000 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015771 | 0.88 | HRH4 (0.53) | CDK4GSK3BMKNK1FGFR1SRC | |
| SCHEMBL445071 | 0.80 | CDK4 (0.55) | CDK4GSK3BMKNK1RAC1KDM4E | |
| SCHEMBL12015766 | 0.80 | MAPT (0.46) | GSK3BKDM4ENPC1LMNAGLA | |
| SCHEMBL1090555 | 0.78 | CXCR4 (0.61) | CDK4GSK3BMKNK1RAC1KDM4E | |
| SCHEMBL5102956 | 0.77 | CDK4 (0.53) | CDK4GSK3BMKNK1RAC1KDM4E | |
| SCHEMBL13384588 | 0.76 | HRH4 (0.52) | NPC1TYRO3MERTKGAS6 | |
| SCHEMBL12015770 | 0.76 | ABL1 (0.47) | KDM4ENPC1LMNAGLAPOLB | |
| SCHEMBL3648590 | 0.75 | MKNK1 (0.61) | CDK4GSK3BMKNK1RAC1KDM4E | |
| SCHEMBL13484501 | 0.74 | NUDT1 (0.45) | KDM4ENPC1RAB9ATYRO3MERTK | |
| SCHEMBL12015762 | 0.74 | ABL1 (0.53) | KDM4ELMNAFGFR1SRCCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8372971-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | CDK4 139/4885GSK3B 2586/4885MKNK1 2968/4885 |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | CDK4 139/4885GSK3B 2586/4885MKNK1 2968/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | CDK4 139/4885GSK3B 2586/4885MKNK1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.